CORT Aug 2023 25.000 call
| Previous close | 1.1000 |
| Open | 1.1000 |
| Bid | 0.6000 |
| Ask | 0.8500 |
| Strike | 25.00 |
| Expiry date | 2023-08-18 |
| Day's range | 1.1000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 38 |
ZacksCorcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
ZacksCorcept Therapeutics (CORT) Lags Q1 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2023. Financial Results Revenue of $105.7 million, compared to $93.7 million in first quarter 2022 Raised 2023 revenue guidance t
ZacksStevanato Group (STVN) Earnings Expected to Grow: Should You Buy?
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a u
- GlobeNewswire
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced the final results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than
- GlobeNewswire
Corcept Therapeutics Announces Preliminary Results of Tender Offer
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greate
ZacksJazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Corcept (CORT) Up 9.6% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Corcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes. Those p
Simply Wall St.Corcept Therapeutics (NASDAQ:CORT) stock performs better than its underlying earnings growth over last three years
By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with...
- Investing.com
5 big stock buybacks: Verisk, Con Edison | Pro Recap
Here are 5 biggest share buyback announcements from the past week you may have missed on InvestingPro. Verisk Analytics (NASDAQ:VRSK) announced that it has entered into accelerated share repurchase agreements with each of Citibank, and Goldman Sachs to repurchase an aggregate of $2.5B of the company's common stock. Morgan Stanley said on Thursday it's adding a position to the company, given (1) industry-standard network effects in an attractive industry, (2) attractive valuation after the company’s return to its traditional property and casualty-focused end markets after selling non-core business segments, and (3) from a portfolio perspective, reduces the Model’s volatility and exposure to consumer discretionary while adding exposure to high-quality industrials.
- GlobeNewswire
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has commenced a modified Dutch Auction tender offer for the purchase of up to 7,500,000 shares of Corcept’s common stock, par value $0.001 per share (
- Simply Wall St.
Corcept Therapeutics Full Year 2022 Earnings: EPS Misses Expectations
Corcept Therapeutics ( NASDAQ:CORT ) Full Year 2022 Results Key Financial Results Revenue: US$401.9m (up 9.8% from FY...
ZacksCorcept's (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
ZacksCorcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2022. Financial Results Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 2
- Simply Wall St.
With 71% ownership of the shares, Corcept Therapeutics Incorporated (NASDAQ:CORT) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Corcept Therapeutics' stock price might be vulnerable...
- GlobeNewswire
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To access the conference call, please dial 877-407-8029 from the United States or +1-201-689-8029 internationally. A replay of
- GlobeNewswire
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci
- Simply Wall St.
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Simply Wall St.
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...
ZacksCorcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
ZacksDurect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
It is hard to get excited after looking at Corcept Therapeutics' (NASDAQ:CORT) recent performance, when its stock has...
